Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(60.0%)
Early Phase 1
1(20.0%)
Phase 1
1(20.0%)
5Total
N/A(3)
Early Phase 1(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07143617Not ApplicableRecruiting

Exploratory Clinical Study on the Safety of STR-P004

Role: collaborator

NCT07363954Not ApplicableNot Yet Recruiting

To Evaluate the Safety and Tolerability of STR-P004 for the Treatment of Immune-mediated Kidney Diseases

Role: lead

NCT07245251Not ApplicableNot Yet Recruiting

To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004

Role: lead

NCT07003178Early Phase 1Not Yet Recruiting

A Study to Evaluate the Safety and Clinical Efficacy of STR-P004

Role: lead

NCT06344975Phase 1Not Yet Recruiting

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults

Role: lead

All 5 trials loaded